references
- Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272�98.
- MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765�74.
- Kaplan NM. How bad are diuretic-induced hypokalaemia and hypercholesterolaemia? Arch Intern Med 1989; 149: 2649.
- Poole-Wilson PA. Hypokalaemia induced by thiazide diuretics in the treatment of hypertension: a cause for concern, not nihilism. Postgrad Med J 1983; 59 Suppl 3: 137.
- Poulter N, Sever P, Thom S. Antihypertensive and adverse biochemical effects of bendrofluazide. Br Med J 1990; 300: 1465.
- Robertson JIS. Hypertension and coronary risk: possible adverse effects of antihypertensive drugs. Am Heart J 1987; 114: S1051�4.
- Weinberger MH. Diuretics and their side-effects. Dilemma in the treatment of hypertension. Hypertension 1988; 11 Suppl II: II-16�II–20.
- Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985; 27: 335�71.
- Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease Part 2, short-term reductionsin blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827�38.
- Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-lineagents: a systematic review and meta-analysis. JAMA 1997; 277: 739�45.
- Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999; 354: 1751�6.
- Hansson L, Lindholm LH, Niskanen L, et al for the Captopril Prevention Project (CAPPP) study group. Effectof angiotensin-converting enzyme inhibition compared withconventional therapy on cardiovascular morbidity andmortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611�16.
- Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366�77.
- Hansson L, Hedner T, Lund-Johansen P, et al for the NORDIL Study Group. Randomised trial of efforts of calcium antagonists compared with diuretics and -blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet 2000; 356: 359�65.
- Blood Pressure Lowering Treatment Trialists� Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955�64.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981�97.
- Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305�15.
- Hansson L, Zanchetti A, Carruthers SG, et al for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755�62.
- Tuomilehto J, Rastenyte D, Birkenhager WH, et al for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677�84.